Riboscience
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Riboscience sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Riboscience: 3 sponsored US clinical trials, 3 recruiting.
Riboscience sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Unresectable Hepatocellular Carcinoma, with 1 trials.
Upper-quartile sponsor footprint
Riboscience sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
NCT07175441
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
NCT06824064
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
NCT05270213
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Riboscience pipeline
3 recruiting of 3 indexed (100% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Advanced Unresectable Hepatocellular Carcinoma (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Riboscience: open-pipeline peers nationwide
Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Riboscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Riboscience page
3 registered trials is a research-attention snapshot, not an endorsement of Riboscience or any single study.
- 3 of Riboscience's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Unresectable Hepatocellular Carcinoma is the condition Riboscience studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Unresectable Hepatocellular Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Riboscience pipeline card: 3 registered trials from official public datasets.Report a data error.